Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

27 de outubro de 2026 atualizado por: Astellas Pharma Global Development, Inc.

A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer. The study will compare these drugs to concurrent chemoradiotherapy that is usually used to treat this cancer (standard of care). The study will enroll patients with muscle-invasive bladder cancer (MIBC) who have cancer that has not spread outside the bladder.

Visão geral do estudo

Descrição detalhada

This study is being conducted to evaluate the combination of enfortumab vedotin + pembrolizumab versus standard of care concurrent chemoradiotherapy, in subjects with previously untreated muscle invasive bladder cancer.

Enfortumab vedotin may be administered for up to 9 cycles or a protocol defined reason for study discontinuation occurs, whichever is first. Pembrolizumab may be administered for a maximum of 17 cycles (3-week cycles) or a protocol-defined reason for study discontinuation occurs, whichever is first. Concurrent chemoradiotherapy may be administered for a maximum of 6.5 weeks.

Tipo de estudo

Intervencional

Inscrição (Estimado)

390

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Quebec
      • Chicoutimi, Quebec, Canadá
        • Recrutamento
        • Site CA01194
      • Montreal, Quebec, Canadá
        • Recrutamento
        • Site CA01071
      • Montreal, Quebec, Canadá
        • Recrutamento
        • Site CA01052
      • Daegu, Coréia do Sul
        • Recrutamento
        • Site KR01113
      • Seongnam-si, Coréia do Sul
        • Recrutamento
        • Site KR01063
      • Seoul, Coréia do Sul
        • Recrutamento
        • Site KR01065
      • Seoul, Coréia do Sul
        • Recrutamento
        • Site KR01084
    • Arkansas
      • Little Rock, Arkansas, Estados Unidos, 72211
        • Recrutamento
        • Arkansas Urology
    • California
      • Santa Barbara, California, Estados Unidos, 93105
        • Recrutamento
        • Samsun Clinic - Ridley-Tree Cancer Center
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80012
        • Recrutamento
        • Rocky Mountain Cancer Center
    • Delaware
      • Newark, Delaware, Estados Unidos, 19713
        • Recrutamento
        • Medical Oncology Hematology Consultants
    • Illinois
      • Hinsdale, Illinois, Estados Unidos, 60521
        • Recrutamento
        • Hope and Healing Clinical Research LLC
      • New Lenox, Illinois, Estados Unidos, 60451
        • Recrutamento
        • Hope and Healing Clinical Research LLC
      • Niles, Illinois, Estados Unidos, 60714
        • Recrutamento
        • Illinois Cancer Specialists
    • Indiana
      • Fort Wayne, Indiana, Estados Unidos, 46825
        • Recrutamento
        • Fort Wayne Medical Oncology and Hematology
    • Michigan
      • Royal Oak, Michigan, Estados Unidos, 48073
        • Recrutamento
        • Comprehensive Urology
    • Missouri
      • Columbia, Missouri, Estados Unidos, 65201
        • Recrutamento
        • Missouri Cancer Associates
      • St Louis, Missouri, Estados Unidos, 63110
        • Recrutamento
        • Siteman Cancer Center
    • Nevada
      • Las Vegas, Nevada, Estados Unidos, 89106
        • Recrutamento
        • Comprehensive Cancer Centers of Nevada - Southwest
    • New York
      • New York, New York, Estados Unidos, 10029
        • Recrutamento
        • Icahn School of Medicine at Mount Sinai
    • Ohio
      • Fairfield, Ohio, Estados Unidos, 45014
        • Recrutamento
        • Oncology Hematology Care Clinical Trials, LLC
    • Oregon
      • Eugene, Oregon, Estados Unidos, 97401
        • Recrutamento
        • Williamette Valley Cancer Institute and Research Center
      • Tigard, Oregon, Estados Unidos, 97223
        • Recrutamento
        • Compass Oncology - West
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37203
        • Recrutamento
        • SCRI Oncology Partners
    • Texas
      • Austin, Texas, Estados Unidos, 78705
        • Recrutamento
        • Texas Oncology
      • Tyler, Texas, Estados Unidos, 75702
        • Recrutamento
        • Texas Oncology - Northeast Texas
    • Virginia
      • Charlottesville, Virginia, Estados Unidos, 22903
        • Recrutamento
        • University of Virginia Comprehensive Cancer Center
      • Norfolk, Virginia, Estados Unidos, 23502
        • Recrutamento
        • Virginia Oncology Associates
      • Kaohsiung City, Taiwan
        • Recrutamento
        • Site TW01117

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Has histologically confirmed initial diagnosis of muscle-invasive bladder cancer (MIBC) with predominant urothelial histology staged cT2-T4aN0M0
  • Tissue comprising muscle-invasive urothelial cancer must be submitted for clinical staging at baseline
  • Eligible for and agree to receive chemoradiotherapy and one of the protocol-specified radiosensitizing chemotherapy regimens
  • Fit for systemic therapy and elect bladder preservation, including participants who are ineligible for or have elected not to undergo cystectomy
  • Has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

Exclusion Criteria:

  • Advanced or metastatic disease (N+, M1), non-urothelial carcinoma, diffuse or multifocal CIS, urothelial carcinoma or histological variant at any site outside the urinary bladder within previous 24 months prior to randomization except Ta/T1/CIS of the upper urinary tract including renal pelvis and ureter if the participant had undergone complete nephrectomy
  • Has received any prior systemic treatment, chemoradiation, and/or radiation for MIBC or NMIBC
  • Prior pelvic radiation for any reason
  • Inadequate bladder function
  • Other active malignancies within 3 years prior to randomization
  • Previously treated with enfortumab vedotin or other MMAE-based antibody-drug conjugates (ADCs)
  • Previously treated with a PD(L)-1 inhibitor, defined as a PD-1 inhibitor or PD-L1 inhibitor
  • Uncontrolled diabetes
  • Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of randomization. Routine antimicrobial prophylaxis is permitted
  • Known active hepatitis B, active hepatitis C, or human immunodeficiency virus (HIV) infection
  • Received major surgery (defined as requiring general anesthesia and >24 hour inpatient hospitalization) within 4 weeks prior to randomization
  • Known severe (≥ Grade 3) hypersensitivity to any enfortumab vedotin excipient contained in the drug formulation of enfortumab vedotin
  • Known genetic disorders associated with radiosensitivity (eg, ataxia telangiectasia, Nijmegen breakage syndrome, Fanconi syndrome)
  • Active keratitis or corneal ulcerations
  • History of autoimmune disease that has required systemic treatment in the past 2 years
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Prior allogeneic stem cell or solid organ transplant
  • Received a live attenuated vaccine within 30 days prior to randomization

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Arm A

Enfortumab vedotin + pembrolizumab (EV + P)

Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle up to cycle 9.

Outros nomes:
  • • Padcev
  • • ASG-22CE
  • • ASG-22Me

IV infusion on Day 1 of every 3-week cycle up to cycle 17.

Outros nomes:
  • Keytruda
Comparador Ativo: Arm B

Concurrent Chemoradiotherapy (cCRT)

64 Gy in 32 fractions over 6.5 weeks administered to the participant's bladder only or the bladder and prophylactically to pelvic nodes.

55 Gy in 20 fractions over 4 weeks administered to the participant's bladder only.

40 mg of cisplatin per meter squared of body surface area, administered once weekly via IV infusion during radiation OR 20 mg of cisplatin per meter squared of body surface area per day on Days 1 and 2 weekly via IV infusion during radiation.

500 mg per meter squared of body surface area per day on Days 1-5 (week 1) and Days 22 26 (week 3) administered as continuous IV infusion during radiation in combination with mitomycin C.

Outros nomes:
  • • 5-Fluorouracil
  • • 5-FU

12 mg per meter squared of body surface area administered as an IV bolus on Day 1 during radiation in combination with fluorouracil.

Outros nomes:
  • • MMC

100 mg per meter squared of body surface area administered once weekly via IV infusion during radiation OR 27 mg per meter squared of body surface area administered twice weekly via IV infusion during radiation

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Bladder-intact Event Free Survival (BI-EFS) by Blinded Independent Central Review (BICR)
Prazo: Up to approximately 45.5 months

BI-EFS is defined as the time from randomization to any of the following events: histologically confirmed persistent or residual MIBC post-treatment confirmed by BICR, histologically confirmed recurrent MIBC by BICR, disease progression by BICR, cystectomy, or death from any cause.

Up to approximately 45.5 months
Overall Survival (OS)
Prazo: Up to approximately 60 months

Time from randomization to death due to any cause.

Up to approximately 60 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Bladder-intact Event Free Survival (BI-EFS) by Investigator
Prazo: Up to approximately 45.5 months

BI-EFS is defined as the time from randomization to any of the following events: histologically confirmed persistent or residual MIBC post-treatment, histologically confirmed recurrent MIBC, disease progression, cystectomy, or death from any cause.

Up to approximately 45.5 months
Complete clinical response (cCR) rate by Blinded Independent Central Review (BICR) and Investigator
Prazo: Up to approximately 60 months

cCR is defined as no radiographic evidence of residual or metastatic disease on imaging, negative cystoscopy, negative pathology except for low-grade Ta, and negative urine cytology.

Up to approximately 60 months
Metastasis-Free Survival (MFS) by Blinded Independent Central Review (BICR) and Investigator
Prazo: Up to approximately 60 months]

Time from randomization to radiologically or pathologically confirmed distant metastasis, or death due to any cause, whichever occurs first.

Up to approximately 60 months]
Time to Cystectomy
Prazo: Up to approximately 60 months

The time from randomization to cystectomy.

Up to approximately 60 months
Disease Free Survival (DFS) by Blinded Independent Central Review (BICR) and Investigator
Prazo: Up to approximately 60 months

The time from cCR to local recurrence or distant metastases, a second primary bladder cancer, or death due to any cause, whichever occurs first.

Up to approximately 60 months
Cystectomy Free Survival (CFS)
Prazo: Up to approximately 60 months

The time from randomization to cystectomy or death due to any cause, whichever occurs first.

Up to approximately 60 months
Number of Participants with Treatment Emergent Adverse Event (TEAE)
Prazo: From start of study treatment up to 30 days after last dose of study drug (approximately up to 1.1 years)

An AE is any untoward medical occurrence in a participant who receives a study treatment without regard to possibility of causal relationship. Treatment-emergent are events between the first dose of study treatment and up to 30 days after the last dose that were absent before treatment or that worsened relative to pretreatment state.

From start of study treatment up to 30 days after last dose of study drug (approximately up to 1.1 years)
Number of Participants with Serious TEAEs
Prazo: From start of treatment up to 90 days after the last dose of study treatment (approximately up to 1.3 years)

An SAE is any AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 90 days after last dose that were absent before treatment or that worsened relative to pretreatment state.

From start of treatment up to 90 days after the last dose of study treatment (approximately up to 1.3 years)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Colaboradores

Investigadores

  • Diretor de estudo: Zejing Wang, MD/PhD, Pfizer

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

11 de maio de 2026

Conclusão Primária (Estimado)

31 de março de 2030

Conclusão do estudo (Estimado)

29 de fevereiro de 2032

Datas de inscrição no estudo

Enviado pela primeira vez

29 de abril de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

29 de abril de 2026

Primeira postagem (Real)

4 de maio de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

28 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

27 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • C5701009
  • EV-309 (Outro identificador: Alias Study Number)
  • 2026-525612-34-00 (Ctis)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Descrição do plano IPD

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever